/images/ppid_59c68470-image-176975505840743716.webp)
/images/ppid_59c68470-image-176950502972177935.webp)
/images/ppid_59c68470-image-176957256262327066.webp)
What is the story about?
Promoters of Rossari Biotech, a Mumbai-based specialty chemicals maker, are exploring options to sell a stake in the company, amid early-stage interest from global private equity funds and a listed strategic player, sources familiar with the discussions told CNBC-TV18.
The talks are at a preliminary and exploratory stage, with no binding offers received and no final decision taken by the promoters, the sources said.
People aware of the matter said the potential stake sale is being driven by the absence of a clearly defined succession roadmap, with no publicly articulated long-term plan for promoter transition so far.
Founded as a specialty chemicals platform focused on high-value formulations, Rossari Biotech has built a strong presence across textiles, personal care and performance chemicals, supplying both domestic and export markets.
From a financial standpoint, the company reported revenue of ₹581.68 crore and net profit of ₹32.77 crore in the quarter ended December 2025, compared with revenue of ₹512.73 crore and net profit of ₹31.70 crore in the corresponding quarter a year earlier.
The current discussions follow an important ownership development in late 2025, when promoter Sunil Srinivasan Chari transferred 15.89% of his stake as a gift to family members and a family trust through an off-market inter-se transfer. While the move did not dilute overall promoter holding, it restructured ownership within the promoter group.
Taken together, the promoter stake realignment and rising private equity interest have brought questions around ownership transition and future governance at Rossari into clear focus.
Promoters of Rossari Biotech have a 68.17% stake in the company at the end of the December quarter.
For now, sources emphasise that the conversations remain non-binding, and it remains to be seen whether the interest culminates in a formal transaction.
Shares of Rossari Biotech are trading 5% higher after the exclusive newsbreak at ₹570.9. The stock is down 20% over the last 12 months.
The talks are at a preliminary and exploratory stage, with no binding offers received and no final decision taken by the promoters, the sources said.
People aware of the matter said the potential stake sale is being driven by the absence of a clearly defined succession roadmap, with no publicly articulated long-term plan for promoter transition so far.
Founded as a specialty chemicals platform focused on high-value formulations, Rossari Biotech has built a strong presence across textiles, personal care and performance chemicals, supplying both domestic and export markets.
From a financial standpoint, the company reported revenue of ₹581.68 crore and net profit of ₹32.77 crore in the quarter ended December 2025, compared with revenue of ₹512.73 crore and net profit of ₹31.70 crore in the corresponding quarter a year earlier.
The current discussions follow an important ownership development in late 2025, when promoter Sunil Srinivasan Chari transferred 15.89% of his stake as a gift to family members and a family trust through an off-market inter-se transfer. While the move did not dilute overall promoter holding, it restructured ownership within the promoter group.
Taken together, the promoter stake realignment and rising private equity interest have brought questions around ownership transition and future governance at Rossari into clear focus.
Promoters of Rossari Biotech have a 68.17% stake in the company at the end of the December quarter.
For now, sources emphasise that the conversations remain non-binding, and it remains to be seen whether the interest culminates in a formal transaction.
Shares of Rossari Biotech are trading 5% higher after the exclusive newsbreak at ₹570.9. The stock is down 20% over the last 12 months.
/images/ppid_59c68470-image-176967003479682018.webp)
/images/ppid_a911dc6a-image-176961206340321936.webp)
/images/ppid_a911dc6a-image-176964063748019626.webp)
